Edition:
United States

Biotechnology & Medical Research

Midatech Pharma Says FY Gross Revenue From Cont Ops Up 96 Pct To 1.9 Mln Stg

April 24 (Reuters) - Midatech Pharma PLC ::TOTAL GROSS REVENUE FOR YEAR FROM CONTINUING OPERATIONS UP 96% TO £1.94M.FY NET LOSS FROM CONTINUING OPERATIONS OF £10.37M.

2:01am EDT

MaxCyte Inc FY Revenue $16.7 Mln

April 24 (Reuters) - MaxCyte Inc ::FY REVENUE $16.7M VERSUS $14.0M.MAXCYTE'S BOARD ANTICIPATES CONTINUED PROGRESS AND STRONG GROWTH IN 2019 FINANCIAL YEAR IN LINE WITH EXPECTATIONS.

2:01am EDT

Pharnext FY Net Loss Widens To 21.3 Million Euros

April 24 (Reuters) - PHARNEXT SA ::FY NET LOSS EUR 21.3 MILLION VERSUS LOSS OF EUR 20.1 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 22.8 MILLION AT DECEMBER 31ST, 2018 VERSUS EUR 12.5 MILLION AT YEAR-END 2017.PHARNEXT HAS CONFIRMED ITS PLAN TO LAUNCH A PHASE 2B STUDY OF PXT864.

1:59am EDT

Mergers & Acquisitions

Expansion & New Markets

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.